| Target Price | $41.82 |
| Price | $39.98 |
| Potential |
4.60%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Roivant Sciences 2027 .
The average Roivant Sciences target price is $41.82.
This is
4.60%
register free of charge
$52.50
31.32%
register free of charge
$36.14
9.61%
register free of charge
|
|
| A rating was issued by 19 analysts: 17 Analysts recommend Roivant Sciences to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2027 of
4.60%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 8.26 | 52.10 |
| 71.57% | 530.74% | |
| EBITDA Margin | -14,841.40% | -2,686.21% |
| 292.09% | 81.90% | |
| Net Margin | -3,629.18% | -2,061.20% |
| 513.02% | 43.20% |
14 Analysts have issued a sales forecast Roivant Sciences 2027 . The average Roivant Sciences sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Roivant Sciences EBITDA forecast 2027. The average Roivant Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Roivant Sciences Analysts have issued a net profit forecast 2027. The average Roivant Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.43 | -1.49 |
| 86.96% | 246.51% | |
| P/E | negative | |
| EV/Sales | 480.55 |
14 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences EPS is
This results in the following potential growth metrics and future valuations:
Roivant Sciences...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 28 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 28 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 07 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


